<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082416</url>
  </required_header>
  <id_info>
    <org_study_id>18C010</org_study_id>
    <nct_id>NCT04082416</nct_id>
  </id_info>
  <brief_title>Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)</brief_title>
  <official_title>A Phase III, Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-exploring Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to initially access the safety and effectivity of RC18 combined
      with standard treatment and Placebo combined with standard therapy in subjects with Moderate
      to severe SLE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SLE Responder Index (SRI) Response Rate</measure>
    <time_frame>Week 52</time_frame>
    <description>At Week 52 the percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score and increasing no more than 0.3 points in PGA and no new BILAG A organ domain score or 1 new BILAG B organ domain scores compared with baseline at the time of assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Physician's global assessment(PGA)</measure>
    <time_frame>Week 52</time_frame>
    <description>Physician's global assessment, PGA.The measurement tool is Visual Analogue Scale/Score（VAS）.The doctor assesses participant's disease activity on a VAS of 0-100 mm on the questionnaire form.The higher values represent a worse outcome.There are not combined subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline or ≤ 7.5 mg/Day，During Weeks 44 Through 52.</measure>
    <time_frame>Week 44 through 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Serological Examination Index</measure>
    <time_frame>week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The flare time after randomization</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>RC18 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received the test group Placebo weekly administered subcutaneously for 52 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo plus standard therapy</intervention_name>
    <description>Standard therapy comprises any of the following (alone or in combination):
corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 160 mg plus standard therapy</intervention_name>
    <description>Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )</description>
    <arm_group_label>RC18 160mg</arm_group_label>
    <other_name>Standard therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active SLE disease#and at least according with 4 of the 11 items of the American
             College of Rheumatology (ACR) criteria 1997.

          -  Age &amp; Gender: Male or female between 18 and 65 years of age inclusive#and the sex
             ratio is not limited

          -  Signed informed consent form#willing or able to participate in all required study
             evaluations and procedures.

          -  SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE
             Disease Activity Index) score ≥ 8 during the screening period.and if there is
             Hypo-complement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should
             be at least 6 at screening .

          -  Autoantibody-positive

          -  on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted
             of any of the following (alone or in combination): cortical
             hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any
             immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate

        Exclusion Criteria:

          -  kidney disease ：Severe lupus nephritis 8 weeks prior to randomization (designed
             as:Urine protein&gt;6g/24h or serum creatinine ( SCr&gt;2.5mg/dL or 221umol/L ) or needing
             for hemodialysis or receipting high dose cortical hormone ≥14 days(
             metacortandracin&gt;100mg/d or equivalent)

          -  Central nervous system disease caused by SLE or non SLE 8 weeks prior to randomization
             (including epilepsy、 mental disease、organic encephalopathy syndrome、cerebrovascular
             accident, encephalitis, central nervous system vasculitis;

          -  there are serious heart, liver, kidney and other important organs and blood, endocrine
             system diseases and medical history;

        Evaluation criteria for severity :

          1. Alanine aminotransferase#ALT#or aspartate aminotransferase (AST) ≥2 upper limit of
             normal (ULN);

          2. Creatinine Clearance (Ccr)&lt;30ml/min;

          3. White Blood Cell Count(WBCs)&lt;2.5x 10(9)/L;

          4. hemoglobin&lt;85g/L;

          5. Platelets&lt;50x 10(9)/L.

               -  Have a historically active hepatitis or active hepatitis or medical
                  history,hepatitis B :Patients with positive HBsAg are excluded.;Hepatitis C:
                  Patients with hepatitis C antibody positive are excluded;

               -  Immune deficiency, uncontrolled severe infection and patients with active or
                  recurrent peptic ulcer;

               -  Pregnant , lactating women and men or women who have birth plans in the past 12
                  months ;

               -  Have a history of allergic reaction to human biological medicines.

               -  Receipt of live vaccine within 1 month;

               -  Have participated in any clinical trial in the first 28 days of the initial
                  screening or 5 times half-life period of the study compound (taking the time for
                  the elderly).

               -  Have received treatment with B cell targeted therapy such as Rituximab or
                  Epratuzumab etc.

               -  Receipt of anti-tumor necrosis factor#interleukin receptor antagonist#

               -  Receipt of IV immunoglobulin(IVIG),prednisone&gt;100mg/d more than 14 days or plasma
                  exchange;

               -  There are active infections (such as herpes zoster, human immunodeficiency virus
                  (HIV) virus infection, active tuberculosis, etc.) during the screening period;

               -  Patients have depression or the significant suicide ideation;

               -  Interleukin(IL)-2, thalidomide, Tripterygium wilfordii and traditional Chinese
                  medicine preparation containing Tripterygium Wilfordii were used within 28 days
                  before randomization

               -  Investigator considers candidates not appropriating for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengchun Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Binghua Xiao</last_name>
    <phone>86-010-58076833</phone>
    <email>Binghua.xiao@remegen.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Remegen，ltd.</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenxiang Wang, M.D.</last_name>
      <phone>86-010-58075563</phone>
      <email>wenxiang.wang@remegen.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 1, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>December 1, 2019</last_update_submitted>
  <last_update_submitted_qc>December 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

